CA
NZ
UK
AU
IND
US
European biotech has attracted a historic flow of venture money this year, with €800 million (≈$912 million) invested so far, according to PitchBook. The surge is pushing the sector toward eclipsing the €1.2 billion benchmark set in 2018 and is already lifting biotech‑focused indices …
ZyVersa Therapeutics, Inc. (OTC: ZVSA) has reported that Min Chul Park, Ph.D. Has left his role on the company’s board. The departure was described as unrelated to any conflict with the organization.
Stifel Financial Corp. Has initiated coverage of Candel Therapeutics with a buy rating and a $22 target price, reflecting the company's growth potential in the healthcare sector. This move is significant for investors, as it highlights the company's prospects and potential for future growth.
The development of a tiny GLP-1 implant by Vivani Medical is set to impact the healthcare sector, particularly in the area of weight loss maintenance. This medical innovation contains semaglutide, a key ingredient in treatments. The healthcare sector is likely to see a shift …
VSee Health has finalized the details for its upcoming annual shareholder meeting, a significant event in its corporate governance schedule. The healthcare technology company disclosed the meeting’s timing and procedural requirements in a recent regulatory filing, offering clarity to investors and stakeholders.
Q32 Bio (NASDAQ: QTTB) announced top‑line data from the second segment of its SIGNAL‑AA Phase 2a study, evaluating the experimental therapy bempikibart in adults with severe alopecia areata.
Sunshine Biopharma Inc. Disclosed a definitive settlement on July 8, 2026 that resolves a dispute with its former subsidiary head, Malek Chamoun. The agreement clears a legal cloud that has lingered over the biotech firm’s recent operational initiatives.
Traws Pharma, Inc. (NASDAQ: TRAW) has finalized an at-the-market (ATM) stock sale agreement, providing the company with a strategic tool to raise capital as needed. This method allows Traws Pharma to issue shares gradually, aligning with the financial strategies commonly adopted by biotech and …
Aligos Therapeutics Inc. (NASDAQ: ALGS) announced the completion of enrollment in its Phase 2 B-SUPREME study for pevifoscorvir sodium, a potential treatment for chronic hepatitis B virus (HBV) infection. The news triggered a 3% decline in pre-market trading, reflecting investor caution as the biotech …
Silo Pharma, Inc. (NASDAQ: SILO) reported the successful closing of a private placement on July 10, 2026, generating gross proceeds in the vicinity of $3.5 million after the deduction of applicable fees. The capital raise was structured to combine equity issuance with a layered …
Please wait processing your request...